Basic Information
| LncRNA/CircRNA Name | lncRNA-NUTF2P3-001 |
| Synonyms | NUTF2P3 |
| Region | GRCh38_9:77580245-77580628 |
| Ensemble | ENSG00000228248 |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | pancreatic cancer |
| ICD-0-3 | C25 |
| Methods | Microarray, qPCR, RNAi, Western blot, Luciferase reporter assay, MTT assay etc. |
| Sample | pancreatic cancer tissues, cell lines (PANC-1 and BXPC-3) |
| Expression Pattern | up-regulated |
| Function Description | lncRNA-NUTF2P3-001 is upregulated in pancreatic cancer cells under hypoxia and CoCl2 treatment, which is attributed to the binding of hypoxia-inducible factor-1a (HIF-1a) to hypoxia response elements (HREs) in the upstream of KRAS promoter. Data from pancreatic cancer patients show a positive correlation between lncRNA-NUTF2P3-001 and KRAS, which is associated with advanced tumor stage and worse prognosis. Hence, our data provide a new lncRNA-mediated regulatory mechanism for the tumor oncogene KRAS and implicate that lncRNA-NUTF2P3-001 and miR-3923 can be applied as novel predictors and therapeutic targets for pancreatic cancer. |
| Pubmed ID | 26755660 |
| Year | 2016 |
| Title | Hypoxia-induced lncRNA-NUTF2P3-001 contributes to tumorigenesis of pancreatic cancer by derepressing the miR-3923/KRAS pathway. |
External Links
| Links for lncRNA-NUTF2P3-001 | GenBank HGNC NONCODE |
| Links for pancreatic cancer | OMIM COSMIC |